Fig. 9From: The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysisThe forest plot shows the relationship between Evusheld administration as prophylaxis and the hospitalization rate of COVID-19 infections in a single-arm subgroupBack to article page